GlobalData on MSN6d
Trevi’s Phase IIb chronic cough success spikes stock by 71%
The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
VanLanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon ...
IRLAB Therapeutics: IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and ...
Le Lézard6d
IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB , a company discovering and developing novel ...
Morningstar6d
IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience
The Phase Ib and Phase IIa studies showed a good safety and tolerability ... effect compared with current treatment options. A Phase IIb study, completed in 2023, showed that mesdopetam has ...
ViiV Healthcare announces data from EMBRACE Phase IIb study
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...